What is the latest update in the femtech market?

The femtech market kicked off 2026 with a strong first quarter, marked by new funding rounds, FDA approvals, policy moves and growing consolidation.

We constantly update this blog post with the latest developments so you always have a fresh picture of where the femtech market stands.

And if you want to better understand this new industry, you can download our pitch covering the femtech market.

Summary table of the most important updates in the femtech market

We define the femtech market as technology-enabled products and services that address women's reproductive and other female-specific health needs.

We include solutions focused on menstrual and cycle health, fertility and contraception, pregnancy and postpartum, menopause, pelvic and sexual health, and clinically oriented tools for conditions that predominantly or uniquely affect women (e.g., breast and gynecological cancers).

We exclude general-purpose health, wellness, fitness, mental health, and consumer apps that are not specifically designed around women's biology, care pathways, or life stages.

You can also get all the latest market news for the month here.

News	Category	Date	Source
Origin raised a major Series B to push pelvic-floor care into the mainstream	Fundraisings	January 28, 2026	PR Newswire
Hologic won FDA clearance that could widen cervical cancer screening options	Product launches	February 4, 2026	Hologic
Wisp made a bold first acquisition to add hybrid care and public-health reach	M&A	January 27, 2026	Wisp
California put menopause care on the policy map with a statewide budget push	Regulations & Policies	February 2, 2026	Governor of California
Costco, Sesame, and IVI RMA teamed up to cut fertility drug costs sharply	Partnerships	March 9, 2026	Business Wire
Maven moved beyond employers and opened nationwide direct access for women	Market expansions	March 11, 2026	Maven Clinic
Federal agencies and AUA launched a menopause-focused care partnership	Partnerships	March 12, 2026	AUA
Hologic said 1.5 billion women still miss basic preventive tests worldwide	Market Research	March 17, 2026	Hologic
Hologic posted another solid quarter in women's health despite deal uncertainty	Financial results	January 29, 2026	Hologic
Congress revived a bipartisan fertility-coverage bill with national ambitions	Regulations & Policies	March 26, 2026	ASRM
Amissa launched an AI layer for a menopause market full of missing data	Breakthrough	January 21, 2026	Amissa
SGS and theblood backed menstrual-blood diagnostics with validation muscle	New tech and infrastructure	February 11, 2026	SGS

How is the femtech market doing now?

How do we define the femtech market?

We define the femtech market as technology-enabled products and services that address women's reproductive and other female-specific health needs.

We include solutions focused on menstrual and cycle health, fertility and contraception, pregnancy and postpartum, menopause, pelvic and sexual health, and clinically oriented tools for conditions that predominantly or uniquely affect women (e.g., breast and gynecological cancers).

We exclude general-purpose health, wellness, fitness, mental health, and consumer apps that are not specifically designed around women's biology, care pathways, or life stages.

This is also the definition we use in our report covering the femtech market.

How big is the femtech market in 2026?

We estimate the femtech market is worth approximately $10 billion in 2026, based on both top-down research estimates and our own bottom-up calculations across fertility, menstrual health, pregnancy, pelvic health, menopause, and clinical tools.

This is not a random guess, if you want to know how we have come up with this estimate, you can read our femtech market size analysis here.

To put that number in perspective, the femtech market is roughly the same size as the global orthopedic devices market ($10.2 billion) or the dental equipment market ($9.8 billion), and it is much larger than telehealth mental health platforms ($6 billion).

The femtech market is still early-stage and highly fragmented, with a maturity score of just 35 out of 100, nearly 4,000 active companies, and no single player controlling more than 10% of the market.

How fast will the femtech market grow in the future?

We believe a realistic growth rate for the femtech market is around 15.5% per year over the next decade, which sits right in the middle of what most aligned research firms are projecting.

At that pace, the femtech market should reach roughly $17.8 billion by 2030 and approximately $42 billion by 2036, growing about 4.3 times its current size in ten years.

That growth rate is faster than the broader digital health market (which grows at about 12% per year) but slower than cutting-edge categories like AI-powered diagnostics (around 22% per year), which makes sense for a sector that mixes mature segments like period tracking with early ones like menopause tech.

What does current funding activity look like in the femtech market?

Our team, who continually updates our femtech market pitch deck, is keeping a close eye on the market and tracking key signals.

One of those signals is fundraising activity across startups. Each month, we refresh this page with a list of startups of the femtech market that have raised funding, and we also publish a quarterly analysis here.

Is funding momentum accelerating or cooling in the femtech market these days?

In Q1 2026, femtech funding activity featured notable rounds like Origin's Series B and Prickly Pear Health's expanded pre-seed, suggesting that investor appetite remains healthy even if the quarter was not dominated by mega-rounds.

Compared to the same period last year, the femtech market continues to attract capital, though the sector has historically grown 3.2 times in venture count but only 1.4 times in funding, meaning more companies are competing for a funding pool that is not growing as fast.

Average deal sizes in femtech remain uneven: female-founded femtech startups still raise about $4.6 million on average, exactly half of the $9.2 million raised by all-male founding teams, a gap that has not meaningfully closed yet. Early-stage rounds like Prickly Pear's $600,000+ pre-seed show small checks still flow, while Origin's Series B indicates later-stage capital is available for companies with traction.

Which categories and business models are attracting capital in the femtech market?

These categories and business models of the femtech market are receiving important fundraising currently:

• Pelvic-floor and physical therapy: Origin raised a Series B to scale its hybrid virtual and in-clinic pelvic care model, showing investors see this as core women's health infrastructure.
• Women's brain health: Prickly Pear Health expanded its pre-seed to over $600,000, proving that even niche femtech subcategories can attract early-stage capital when the angle is clear.
• Enterprise B2B2C models: companies like Maven Clinic continue to demonstrate superior unit economics at $2,300 per enrolled member, making employer-sponsored women's health a magnet for growth-stage funding.

The pattern is clear: femtech investors in Q1 2026 are backing companies that solve specific, underserved problems in women's health rather than broad consumer wellness plays.

Who's writing the most checks in the femtech market?

These investors are being very active when it comes to fundraising in the femtech market:

• SJF Ventures led Origin's Series B, positioning itself as a key backer in the growing pelvic-floor and women's physical therapy space.
• Blue Venture Fund joined Origin's round, showing continued interest in women's health companies with hybrid care models.
• Emmeline Ventures invested in Prickly Pear Health's pre-seed, backing a niche femtech category (women's brain health) that most funds overlook.

The investor mix in Q1 2026 shows both specialized women's health funds and impact-oriented firms stepping up, which is a good sign for founders looking beyond traditional healthcare VCs.

Any big acquisitions or IPOs in the last three months in the femtech market?

These are the big acquisitions and IPOs that happened recently in the femtech market:

• Wisp acquired TBD Health, its first-ever acquisition, adding 50-state sexual-health and diagnostics infrastructure plus public-health and health-system relationships to its telehealth platform.

Wisp's move signals that consolidation is arriving in women's telehealth, with the winners building hybrid models that combine e-commerce, testing, virtual care and enterprise distribution.

How are companies in the femtech market performing overall?

We are watching this market everyday, because we need to constantly update our pitch deck. Here is a couple of things we have noticed.

Are there any standout success metrics or financial results in the femtech market?

Yes, Q1 2026 brought one major financial result worth highlighting in the femtech market:

• Hologic reported Q1 fiscal 2026 revenue of $1.05 billion, with breast health up 1.8% and surgical revenue up 8.7%, proving that women's health technology generates real, large-scale revenue.

Hologic's results remind us that the femtech market already has billion-dollar incumbents, which means startups need sharp differentiation to compete.

Have there been any major partnerships in the femtech market?

Q1 2026 was actually a strong quarter for partnerships in the femtech market:

• Costco, Sesame, and IVI RMA launched a fertility partnership that combines care navigation, specialty treatment, and medication pricing with up to 80% drug cost savings for Costco members.
• The American Urological Association partnered with HHS, FDA, and CDC to improve postmenopausal care, positioning menopause as a serious public-health issue.
• Maven and Color linked cancer care to fertility preservation in a single pathway, helping patients facing cancer treatment make fertility decisions earlier.
• INVO Fertility's Wisconsin clinic joined the Progyny network, gaining access to employer-covered patients and expanding its addressable market.

The common thread across these partnerships is distribution: femtech companies in Q1 2026 are partnering to reach more women through employers, retailers, and federal agencies rather than going it alone.

Have there been any notable technology or infrastructure breakthroughs in the femtech market?

Yes, several breakthroughs stood out in Q1 2026 in the femtech market:

• Hologic won FDA approval for its Aptima HPV Assay as a primary screening option, the only FDA-approved mRNA-based assay in this category, giving providers another route for cervical cancer screening.
• Amissa launched an AI-powered menopause care platform that creates a standardized symptom data layer, helping clinicians assess severity and track change over time in a category full of missing data.
• SGS partnered with theblood to validate menstrual-blood diagnostics, adding regulatory-grade validation support to a novel diagnostic pathway that could open a new platform for women's health testing.
• Maven launched a Clinical Research Institute to build clinical evidence in women's and family health, partnering with Harvard Medical School, OURA, and Posterity.

These breakthroughs share one thing: they are all about building the missing infrastructure (data, evidence, validation, regulation) that the femtech market needs to scale beyond consumer apps.

Have any companies restructured or shifted pricing or business model in the femtech market?

One significant business model shift happened during Q1 2026 in the femtech market:

• Maven Clinic opened direct-to-consumer access nationwide, moving beyond its employer-only model to let any woman access its platform directly, a major shift for one of the most prominent B2B femtech companies.

Maven's move blurs the line between B2B and B2C in femtech, and it could push other employer-focused platforms to think about expanding their channels too.

Are there any other notable wins or successes in the femtech market?

There were no other major wins or successes beyond those already covered in the sections above during Q1 2026 in the femtech market.

What is the overall sentiment in the femtech market right now?

Are there any notable recent opinion pieces, thought leadership about the femtech market?

We did not spot any standout opinion pieces or thought leadership essays during Q1 2026 in the femtech market that would warrant a separate mention here.

Are there any interesting and recent market research reports about the femtech market?

Yes, two market research reports stood out in Q1 2026 in the femtech market:

• Hologic released its fifth Global Women's Health Index with Gallup, finding that more than 1.5 billion women and girls aged 15+ were not tested in the past year for cancer, blood pressure, diabetes, or STIs.
• Kearney launched the [w]Health Healthcare and Life Sciences Index with UNFPA and the HBA Think Tank, creating a new baseline for measuring how healthcare companies handle women's health across research, care, investment, and data.

These two reports matter because they give the femtech market something it has lacked: real benchmarks and data to measure progress, not just promises.

Have there been any regulatory changes, policy updates, or new compliance requirements in the femtech market?

Q1 2026 was an active quarter for policy in the femtech market:

• Governor Newsom proposed expanding menopause healthcare in California through a 2026-27 budget trailer-bill proposal, putting menopause into mainstream state health policy for the first time.
• The bipartisan HOPE Act was reintroduced in Congress, aiming to mandate insurance coverage for infertility diagnosis, treatment, and fertility preservation nationwide.

Both of these moves could reshape the femtech market's demand side: if coverage expands at the state and federal level, the companies ready for payer workflows will benefit the most.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living “market pitch” documents for emerging markets: from AI to synthetic biology and new proteins. Instead of digging through outdated PDFs, random blog posts, and hallucinated LLM answers, our clients get a clean, visual, always-updated view of what’s really happening. We map the key players, deals, regulations, metrics and signals that matter so you can decide faster whether a market is worth your time. Want to know more? Check out our about page.

How we created this content 🔎📝

At New Market Pitch, we kept seeing the same problem: when you look at a new market, the data is either missing, paywalled, or buried in 300-page reports that feel like they were written in the 80s. On the other side, LLMs and random blog posts give you confident answers with no sources, and sometimes they just make things up. That’s not good enough when you’re about to invest real money or launch a company.

So we decided to fix the experience. For each market we cover, we build a structured database and update it on a regular basis. We track funding rounds, fund memos, M&A moves, partnerships, new products, policy changes, and the real activity of startups and incumbents. Then we turn all of that into a clear “market pitch” that shows where the opportunities are and how people actually win in that space.

Every key data point is checked, sourced, and put back into context by our team. That’s how we can give you both speed and reliability: fast coverage of new markets, without the usual guesswork.